553 related articles for article (PubMed ID: 19104515)
1. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.
Kirn DH; Thorne SH
Nat Rev Cancer; 2009 Jan; 9(1):64-71. PubMed ID: 19104515
[TBL] [Abstract][Full Text] [Related]
2. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
Breitbach CJ; Thorne SH; Bell JC; Kirn DH
Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
[TBL] [Abstract][Full Text] [Related]
3. Application of Oncolytic Poxviruses: An Emerging Paradigm in Cancer Therapy.
Chakraborty P; Kumar R; Karn S; Raviya DD; Mondal P
Adv Exp Med Biol; 2024; 1451():369-381. PubMed ID: 38801591
[TBL] [Abstract][Full Text] [Related]
4. Replicating poxviruses for human cancer therapy.
Kim M
J Microbiol; 2015 Apr; 53(4):209-18. PubMed ID: 25845536
[TBL] [Abstract][Full Text] [Related]
5. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic potential of oncolytic vaccinia virus.
Thorne SH
Immunol Res; 2011 Aug; 50(2-3):286-93. PubMed ID: 21717084
[TBL] [Abstract][Full Text] [Related]
7. A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.
Thirunavukarasu P; Sathaiah M; Gorry MC; O'Malley ME; Ravindranathan R; Austin F; Thorne SH; Guo ZS; Bartlett DL
Mol Ther; 2013 May; 21(5):1024-33. PubMed ID: 23439499
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
9. The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses.
Mundi N; Um S; Yoo J; Rizzo G; Black M; Pinto N; Palma DA; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Virus Res; 2014 Sep; 190():53-9. PubMed ID: 25038405
[TBL] [Abstract][Full Text] [Related]
10. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
12. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.
Thorne SH; Hwang TH; O'Gorman WE; Bartlett DL; Sei S; Kanji F; Brown C; Werier J; Cho JH; Lee DE; Wang Y; Bell J; Kirn DH
J Clin Invest; 2007 Nov; 117(11):3350-8. PubMed ID: 17965776
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
[TBL] [Abstract][Full Text] [Related]
15. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.
Evgin L; Vähä-Koskela M; Rintoul J; Falls T; Le Boeuf F; Barrett JW; Bell JC; Stanford MM
Mol Ther; 2010 May; 18(5):896-902. PubMed ID: 20160706
[TBL] [Abstract][Full Text] [Related]
16. Deletion of
Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
[TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
Al Yaghchi C; Zhang Z; Alusi G; Lemoine NR; Wang Y
Immunotherapy; 2015; 7(12):1249-58. PubMed ID: 26595180
[TBL] [Abstract][Full Text] [Related]
18. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
19. Virotherapy--cancer targeted pharmacology.
Tedcastle A; Cawood R; Di Y; Fisher KD; Seymour LW
Drug Discov Today; 2012 Mar; 17(5-6):215-20. PubMed ID: 22198165
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]